Вот предупреждение по безопасности приема топамакса. Это мы все видели и рассказывали. Некоторые нам не верили.
Important Safety Information
TOPAMAX has been associated with serious adverse events including: hyperchloremic, non-anion gap metabolic acidosis (lowering of serum bicarbonate levels) measurement of baseline and periodic serum bicarbonate levels is recommended; acute myopia and secondary angle closure glaucoma – patients should seek medical attention if they experience blurred vision or ocular pain; oligohydrosis and hyperthermia-occurs most often in hot weather and in children; cognitive/psychiatric side effects, including somnolence, fatigue, cognitive dysfunction, and psychiatric/behavioral disturbances; hyperammonemia with or without encephalopathy-associated with the concomitant use of valproic acid; and kidney stones – patients should maintain an adequate fluid intake to minimize the risk of renal stone formation.
As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50 mg/day group) in adults were: paresthesia, weight decrease, somnolence, anorexia, dizziness, and difficulty with memory; and in children: weight decrease, upper respiratory tract infection, paresthesia, anorexia, diarrhea, and mood problems.
In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were somnolence, dizziness, nervousness, ataxia, fatigue, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, and diplopia; and in children (5 to 9 mg/kg/day): fatigue, somnolence, anorexia, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.
In women taking combination oral contraceptives with TOPAMAX, a significant decrease in the estrogen exposure has been show at TOPAMAX doses ≥ 200 mg/day. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered.
© Ortho-McNeil Neurologics, Inc. 1999-2006. All rights reserved.